Insights into the Future Growth Potential of the Vasomotor Menopausal Symptoms (VMS) Treatment Market 2024-2033
Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!
What is the Expected Growth Rate of the Vasomotor Menopausal Symptoms (VMS) Treatment Market from 2024 to 2033?
The vasomotor menopausal symptoms (VMS) treatment market size will grow from $16.6 billion in 2023 to $17.86 billion in 2024 at a compound annual growth rate (CAGR) of 7.6%. This growth is attributed to hormone replacement therapy (HRT), menopause awareness, pharmaceutical developments, and consumer demand.
The vasomotor menopausal symptoms (VMS) treatment market is projected to reach $23.11 billion by 2028, with a CAGR of 6.7%. The growth is attributed to personalized medicine, non-hormonal innovations, dietary interventions, and telemedicine. Trends include natural and alternative approaches, botanical remedies, menopause support groups, and cognitive behavioral therapy.
Claim Your Free Sample of the Global Vasomotor Menopausal Symptoms (VMS) Treatment Market Report Today!
https://www.thebusinessresearchcompany.com/sample.aspx?id=13051&type=smp
The growing menopause population is anticipated to drive the vasomotor menopausal symptoms treatment market. Menopause, affecting women typically aged 45-55, increases the demand for treatment options like hormone therapy for symptoms such as hot flashes. The Cuyuna Regional Medical Center projected 1.1 billion menopausal women globally by 2025. Thus, the expanding menopausal population is boosting the vasomotor menopausal symptoms treatment market.
1) By Drug Class: Antidepressants, Fluoxetine, Paroxetine, Sertraline, Hormone Therapy, Anticonvulsant, Phenytoin, Phenobarbital, Other Drug Classes
2) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-Users
In the vasomotor menopausal symptoms treatment market, companies are developing products like Veozah and obtaining approvals to address unmet medical needs. For instance, in May 2023, Astellas Pharma Inc. received FDA approval for Veozah (fezolinetant), a non-hormonal treatment for menopausal vasomotor symptoms (VMS). This drug, the first neurokinin 3 receptor antagonist approved for VMS, offers an alternative treatment for women who prefer not to use hormone therapy. The approval of Veozah represents a new, hormone-free option for managing these symptoms, especially for women unable or unwilling to use hormone-based treatments.
Order Now for Fast Delivery of Your Vasomotor Menopausal Symptoms (VMS) Treatment Market Report!
North America was the largest region in the night vision devices market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the night vision devices market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The Vasomotor Menopausal Symptoms (VMS) Treatment Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the vasomotor menopausal symptoms (vms) treatment market, its market share, and analyzes key competitors along with their market positions.
The Table Of Content For The Vasomotor Menopausal Symptoms (VMS) Treatment Market Include
1. Vasomotor Menopausal Symptoms (VMS) Treatment Market Executive Summary
2. Vasomotor Menopausal Symptoms (VMS) Treatment Market Segments
3. Vasomotor Menopausal Symptoms (VMS) Treatment Market Size And Template Market Growth Rate
4. Key Vasomotor Menopausal Symptoms (VMS) Treatment Market Trends
5. Major Vasomotor Menopausal Symptoms (VMS) Treatment Market Drivers
……
25. Key Mergers And Acquisitions In The Vasomotor Menopausal Symptoms (VMS) Treatment Market
26. Top Vasomotor Menopausal Symptoms (VMS) Treatment Companies
27. Vasomotor Menopausal Symptoms (VMS) Treatment Market Opportunities And Strategies
28. Vasomotor Menopausal Symptoms (VMS) Treatment Market, Conclusions And Recommendations
29. Appendix
Discover Related Reports by The Business Research Company:
Postmenopausal Osteoporosis Treatment Global Market Report 2024
Menopausal Hot Flashes Global Market Report 2024
https://www.thebusinessresearchcompany.com/report/menopausal-hot-flashes-global-market-report
PMS and Menstrual Health Supplements Global Market Report 2024
Learn More About The Business Research Company
The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
